Welcome to InfiCure Bio

InfiCure Bio is a life science company focusing on preclinical development and validation of drugs that target chronic inflammatory and fibrotic conditions.

Based on a panel of in vivo models for these conditions including a proprietary model for chronic inflammation and fibrosis, we offer effect tests of anti-inflammatory and anti-fibrotic drugs.

Founded on extensive experience and expertise in immunology, inflammation and fibrosis research, InfiCure Bio offers a proficient and flexible processing of drug validation projects in this area.

News

InfiCure Bio part of industry report 2018

InfiCure Bio is one of the companies on the map of Swedish precision medicine industry companies 2018. In the report “Precision Medicine The Swedish Industry Guide 2018”, SwedenBIO has made a map of Swedish companies [...]

  • Maria

New Product Manager at InfiCure Bio

Maria Hörnberg is now the new Product Manager at InfiCure Bio. Maria has a PhD in Molecular Biology and prior to her position at InfiCure Bio she was the coordinator of the Transgene Core Facility at Umeå [...]

  • Vinnova

Innovative Start up Phase II grant

InfiCure Bio was awarded Innovative Start up Phase II from Vinnova. This opens up an additional market segment for InfiCure Bio, since the grant will fund the validation of additional models for NASH.    

Anti-Fibrotic Drug Development Summit

InfiCure Bio is one of the sponsors of Anti-Fibrotic Drug Development Summit (AFDD) at Hyatt Regency in Boston. The AFDD brings together important experts in different areas of drug development with the aim to find better solutions [...]